[ad_1] By Peter Landers TOKYO–Japanese drugmaker Shionogi & Co. said Monday that it plans to start a global Phase 3 trial of its Covid-19 pill as soon as late February and is in discussions with U.S. and European regulators over the trial. Shionogi said a Phase 2a trial showed that the virus was eliminated more […]
Continue Reading
[ad_1] Merck cited six preclinical studies performed by researchers outside the company. The examples include research published this week in the New England Journal of Medicine that found molnupiravir among several Covid-19 antiviral drugs that “may show efficacy for treating patients infected with the Omicron variant.” Molnupiravir, which was cleared for use in the U.S. […]
Continue Reading
[ad_1] An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS Register now for FREE unlimited access to Reuters.com Register […]
Continue Reading